- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib in Advanced Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Liver Cancer
Volume 6, Issue 4, Pages 253-263
Publisher
S. Karger AG
Online
2017-08-29
DOI
10.1159/000479573
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
- (2017) Toshiyuki Tamai et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study
- (2016) Masatoshi Kudo et al. LIVER INTERNATIONAL
- Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives
- (2016) Masatoshi Kudo Liver Cancer
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
- (2015) M. Ikeda et al. CLINICAL CANCER RESEARCH
- Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
- (2015) Takeshi Terashima et al. HEPATOLOGY RESEARCH
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?
- (2015) Liver Cancer
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Why Does Every Hepatocellular Carcinoma Clinical Trial Using Molecular Targeted Agents Fail?
- (2012) Liver Cancer
- Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival
- (2011) Goh Eun Chung et al. RADIOLOGY
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started